By Jason Derry --
Crucell N.V. has announced a
cross-licensing agreement with Merck & Co. relating
to Crucell's vaccine technology. The
deal allows Merck to use Crucell's technology in certain vaccine fields that
have yet to be publicly disclosed, while Crucell will be able to manufacture
its Advac®-based vaccines on a larger scale using Merck's large scale
manufacturing technology. Merck already
has a license to Crucell's PER.C6® cell line, which can be used
for vaccine and protein production.
Crucell is a biotechnology company headquartered in The
Netherlands, and focuses its research and development efforts on vaccines and
antibodies for preventing or treating infectious diseases.
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments